GLP-1

News

Novo makes fresh obesity play with $2.2bn Septerna deal

A new licensing deal with Septerna suggests Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity.

News

FDA decision on oral Wegovy coming in Q4

Novo Nordisk has had its NDA for an oral formulation of Wegovy accepted by the FDA. It would be the first obesity-targeted GLP-1 in pill form.

News

Lilly soars on first data for oral obesity candidate

Shares in Eli Lilly rose sharply in pre-market trading today after it reported phase 3 results for oral diabetes and weight-loss drug orforglipron.

News

Pfizer's weight-loss aspirations are dealt a heavy blow

Pfizer has been forced to discontinue its oral GLP-1 receptor agonist danuglipron after seeing signs of liver toxicity in late-stage clinical testing.

R&D

Obesity and the endoscopy space: Innovative, minimally invas...

According to the World Health Organization (WHO), in 2022, 2.5 billion adults aged 18 years and older were overweight, including over 890 million adults who were living with

Market Access